[Kidney transplant].
The kidney transplant is the therapy of choice for the majority of the causes of chronic terminal kidney insufficiency, because it improves the quality of life and survival in comparison with dialysis. A kidney transplant from a live donor is an excellent alternative for the young patient in a state of pre-dialysis because it offers the best results. Immunosuppressive treatment must be individualised, seeking immunosuppressive synergy and the best safety profile, and must be adapted to the different stages of the kidney transplant. In the follow-up to the kidney transplant, cardiovascular risk factors and tumours must be especially taken into account, given that the death of the patient with a working graft is the second cause of loss of the graft following the first year of the transplant. The altered function of the graft is a factor of independent cardiovascular mortality that will require follow-up and the control of all its complications to postpone the entrance in dialysis.
Martín
P
P
Servicio de Nefrología, Clínica Universitaria, Universidad de Navarra, Pamplona, 31008, Spain.
Errasti
P
P
D000208:Acute Disease; D000367:Age Factors; D000368:Aged; D001706:Biopsy; D002102:Cadaver; D000075202:Contraindications; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000628:therapy; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D007668:Kidney / Q000473:pathology; D016030:Kidney Transplantation / Q000009:adverse effects / Q000473:pathology; D019520:Living Donors; D008297:Male; D018579:Patient Selection; D011182:Postoperative Care; D011183:Postoperative Complications; D012307:Risk Factors; D013997:Time Factors; D014019:Tissue Donors
D007166:Immunosuppressive Agents